v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY - SECURITIZE, INC. AND SUBSIDIARIES - USD ($)
Total
Securitize, Inc. and Subsidiaries
J Digital 6 Warrants
Securitize, Inc. and Subsidiaries
Class A
Securitize, Inc. and Subsidiaries
Redeemable Convertible Preferred Stock
Securitize, Inc. and Subsidiaries
Series B-4 Redeemable Convertible Preferred Stock
Securitize, Inc. and Subsidiaries
Series B-3 Redeemable Convertible Preferred Stock
Securitize, Inc. and Subsidiaries
Series B-2 Redeemable Convertible Preferred Stock
Securitize, Inc. and Subsidiaries
Series B-1 Redeemable Convertible Preferred Stock
Securitize, Inc. and Subsidiaries
Series A Redeemable Convertible Preferred Stock
Securitize, Inc. and Subsidiaries
Common Stock
Common Stock
Securitize, Inc. and Subsidiaries
Common Stock
Class A
Securitize, Inc. and Subsidiaries
Treasury Stock
Securitize, Inc. and Subsidiaries
Stockholder 
Notes
Securitize, Inc. and Subsidiaries
Additional
Paid-In
Capital
Securitize, Inc. and Subsidiaries
Accumulated
Deficit
Securitize, Inc. and Subsidiaries
Accumulated 
Other
Comprehensive
Income
Securitize, Inc. and Subsidiaries
Beginning balance (in shares) at Dec. 31, 2023   11,398,728       1,667,734 1,219,998 2,630,197 2,881,387 2,999,412                
Beginning balance at Dec. 31, 2023   $ 116,995,645       $ 36,023,055 $ 21,969,898 $ 23,889,549 $ 21,380,220 $ 13,732,923                
Ending balance (in shares) at Dec. 31, 2024   11,398,728 0     1,667,734 1,219,998 2,630,197 2,881,387 2,999,412                
Ending balance at Dec. 31, 2024   $ 116,995,645 $ 0     $ 36,023,055 $ 21,969,898 $ 23,889,549 $ 21,380,220 $ 13,732,923                
Beginning balance (in shares) at Dec. 31, 2023                       8,856,513 0          
Beginning balance at Dec. 31, 2023   (76,846,500)                   $ 886 $ 0 $ (1,599,978) $ (3,000,000) $ 20,152,307 $ (92,760,445) $ 360,730
Beginning balance, Treasury (in shares) at Dec. 31, 2023                           150,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Contingent consideration payable in common stock   53,539                           53,539    
Foreign currency translation adjustment   106,250                               106,250
Stock-based compensation expense   404,041                           404,041    
Interest receivable associated with notes receivable from stockholder   (423,744)                         (423,744)      
Net income (loss)   $ (24,287,668)                                
Ending balance (in shares) at Dec. 31, 2024   8,706,513   0               8,856,513 0          
Ending balance at Dec. 31, 2024   $ (100,994,082)                   $ 886 $ 0 $ (1,599,978) (3,423,744) 20,609,887 (117,048,113) 466,980
Ending balance, Treasury (in shares) at Dec. 31, 2024   150,000                       150,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Beginning balance   $ (100,994,968)                                
Deemed dividend to preferred shareholders (Note 12)   $ 1,493,539           $ 498,249 $ 27,527 $ 967,763                
Exchange of Common stock to Series B-4 redeemable convertible preferred stock (in shares)   421,723       421,723                        
Exchange of Common stock to Series B-4 redeemable convertible preferred stock   $ 6,325,845       $ 6,325,845                        
Ending balance (in shares) at Mar. 31, 2025   11,820,451 0     2,089,457 1,219,998 2,630,197 2,881,387 2,999,412                
Ending balance at Mar. 31, 2025   $ 124,815,029 $ 0     $ 42,348,900 $ 21,969,898 $ 24,387,798 $ 21,407,747 $ 14,700,686                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Foreign currency translation adjustment   73,228                               73,228
Stock-based compensation expense   7,431,004                           7,431,004    
Deemed dividend to preferred shareholders (Note 12)   (1,493,539)                           (1,493,539)    
Exercise of stock options (in shares)                       62,164 1,773          
Exercise of stock options   3,020                   $ 6       3,014    
Exchange of Common stock to Series B-4 redeemable convertible preferred stock (in shares)                       (421,723)            
Exchange of Common stock to Series B-4 redeemable convertible preferred stock   (6,325,887)                   $ (42)       (6,325,845)    
Issuance of common stock associated with the Theorem business combination (in shares)                       203,822            
Issuance of common stock associated with the Theorem business combination   0                   $ 20       (20)    
Interest receivable associated with notes receivable from stockholder   (38,566)                         (38,566)      
Net income (loss)   (5,124,857)                             (5,124,857)  
Ending balance (in shares) at Mar. 31, 2025                       8,700,776 1,773          
Ending balance at Mar. 31, 2025   $ (106,469,679)                   $ 870 $ 0 $ (1,599,978) (3,462,310) 20,224,501 (122,172,970) 540,208
Ending balance, Treasury (in shares) at Mar. 31, 2025                           150,000        
Beginning balance (in shares) at Dec. 31, 2024   11,398,728 0     1,667,734 1,219,998 2,630,197 2,881,387 2,999,412                
Beginning balance at Dec. 31, 2024   $ 116,995,645 $ 0     $ 36,023,055 $ 21,969,898 $ 23,889,549 $ 21,380,220 $ 13,732,923                
Increase (Decrease) in Temporary Equity [Roll Forward]                                    
Share-based compensation expense   731,076 $ 731,076                              
Deemed dividend to preferred shareholders (Note 12)   $ 1,493,539           $ 498,249 $ 27,527 $ 967,763                
Exchange of Common stock to Series B-4 redeemable convertible preferred stock (in shares)   421,723       421,723                        
Exchange of Common stock to Series B-4 redeemable convertible preferred stock   $ 6,325,845       $ 6,325,845                        
Ending balance (in shares) at Dec. 31, 2025   11,820,451 0   11,820,451 2,089,457 1,219,998 2,630,197 2,881,387 2,999,412                
Ending balance at Dec. 31, 2025   $ 125,546,105 $ 731,076   $ 124,815,029 $ 42,348,900 $ 21,969,898 $ 24,387,798 $ 21,407,747 $ 14,700,686                
Beginning balance (in shares) at Dec. 31, 2024   8,706,513   0               8,856,513 0          
Beginning balance at Dec. 31, 2024   $ (100,994,082)                   $ 886 $ 0 $ (1,599,978) (3,423,744) 20,609,887 (117,048,113) 466,980
Beginning balance, Treasury (in shares) at Dec. 31, 2024   150,000                       150,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Foreign currency translation adjustment   $ 627,402                               627,402
Stock-based compensation expense   11,411,837                           11,411,837    
Deemed dividend to preferred shareholders (Note 12)   $ (1,493,539)                           (1,493,539)    
Exercise of stock options (in shares)   293,768                   62,164 293,768          
Exercise of stock options   $ 534,580                   $ 6 $ 29     534,545    
Exchange of Common stock to Series B-4 redeemable convertible preferred stock (in shares)                       (421,723)            
Exchange of Common stock to Series B-4 redeemable convertible preferred stock   (6,325,845)                   $ (42)       (6,325,803)    
Issuance of common stock associated with the Theorem business combination (in shares)                       203,822            
Issuance of common stock associated with the Theorem business combination   0                   $ 20       (20)    
Interest receivable associated with notes receivable from stockholder   (145,111)                         (145,111)      
Repayment of notes receivable from stockholder   3,568,855                         3,568,855      
Net income (loss)   $ (48,454,725)                             (48,454,725)  
Ending balance (in shares) at Dec. 31, 2025   8,550,776   293,768             10,000 8,700,776 293,768          
Ending balance at Dec. 31, 2025 $ 1 $ (141,270,628)                 $ 1 $ 870 $ 29 $ (1,599,978) $ 0 24,736,907 (165,502,838) 1,094,382
Ending balance, Treasury (in shares) at Dec. 31, 2025   150,000                       150,000        
Increase (Decrease) in Temporary Equity [Roll Forward]                                    
Share-based compensation expense     $ 438,645                              
Ending balance (in shares) at Mar. 31, 2026     0   11,820,451 2,089,457 1,219,998 2,630,197 2,881,387 2,999,412                
Ending balance at Mar. 31, 2026   $ 125,984,750 $ 1,169,721   $ 124,815,029 $ 42,348,900 $ 21,969,898 $ 24,387,798 $ 21,407,747 $ 14,700,686                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Foreign currency translation adjustment   49,886                               49,886
Stock-based compensation expense   397,943                           397,943    
Exercise of stock options (in shares)                         45,404          
Exercise of stock options   81,964                     $ 4     81,960    
Net income (loss)   $ (7,932,652)                             (7,932,652)  
Ending balance (in shares) at Mar. 31, 2026   8,550,776   332,235             10,000 8,700,776 339,172          
Ending balance at Mar. 31, 2026 $ 1 $ (148,673,487)                 $ 1 $ 870 $ 33 $ (1,599,978)   $ 25,216,810 $ (173,435,490) $ 1,144,268
Ending balance, Treasury (in shares) at Mar. 31, 2026   150,000                       150,000